Fujian Aonong Biological Technology Group Incorporation Yönetim

Yönetim kriter kontrolleri 3/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

You Lin Wu

İcra Kurulu Başkanı

CN¥625.7k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	9.3yrs
CEO sahipliği	8.7%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Shares Not Telling The Full Story

Aug 22

Market Cool On Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Revenues Pushing Shares 30% Lower

May 02

CEO

You Lin Wu (46 yo)

9.3yrs

Görev süresi

CN¥625,700

Tazminat

Mr. You Lin Wu serves as the Chairman of the Board of Directors and General Manager at Fujian Aonong Biological Technology Group Incorporation Limited and has been its Director since August 27, 2015. Mr. W...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
You Lin Wu	Chairman of the Board of Directors & GM	no data	CN¥625.70k	8.67% CN¥ 263.2m
Qiang Lin	Deputy GM	less than a year	Veri yok	Veri yok
Jun Guo	Deputy GM & GM of Capital Management Centre	less than a year	Veri yok	Veri yok
Jingquan Yang	Deputy General Manager	3.1yrs	CN¥598.30k	0.016% CN¥ 499.0k
Jianping Yang	Accounting Supervisor	no data	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

45.5yo

Ortalama Yaş

Deneyimli Yönetim: 603363's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
You Lin Wu	Chairman of the Board of Directors & GM	9.3yrs	CN¥625.70k	8.67% CN¥ 263.2m
Feng Liu	Independent Director	3.1yrs	CN¥120.00k	0.0033% CN¥ 99.9k
Luying Zheng	Independent Director	3.1yrs	CN¥120.00k	Veri yok
Chunxiang Ai	Independent Director	3.1yrs	CN¥120.00k	Veri yok
Jun Kuang	Director	less than a year	CN¥485.10k	Veri yok
Zhirong Lian	Supervisor	less than a year	Veri yok	0.0026% CN¥ 78.7k

3.1yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 603363's board of directors are considered experienced (3.1 years average tenure).

Fujian Aonong Biological Technology Group Incorporation Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 06, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.32 loss per share (vs CN¥0.56 loss in 3Q 2023)

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.71 loss in 2Q 2023)

Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Shares Not Telling The Full Story

Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2024 Results on Aug 31, 2024

Fujian Aonong Biological Technology Group Incorporation Limited, Annual General Meeting, Jun 06, 2024

Market Cool On Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Revenues Pushing Shares 30% Lower

Less than half of directors are independent

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Fujian Aonong Biological Technology Group Incorporation Limited to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.56 loss per share (vs CN¥0.12 profit in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.71 loss per share (vs CN¥0.42 loss in 2Q 2022)

First quarter 2023 earnings released: CN¥0.21 loss per share (vs CN¥0.54 loss in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.50 loss in 3Q 2021)

Now 20% undervalued after recent price drop

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.50 loss per share (vs CN¥0.25 profit in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.54 loss per share (vs CN¥0.33 profit in 2Q 2020)

Price target increased to CN¥29.16

First quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.27 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.95 (vs CN¥0.054 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥15.51

Investor sentiment improved over the past week

New 90-day low: CN¥12.37

New 90-day low: CN¥13.15

New 90-day low: CN¥13.54

Fujian Aonong Biological Technology Group Incorporation Limited to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥13.63

Liu Xueke, Su Guoyang, Wu Boyuan, and Liu Lianlong agreed to acquire 21% stake in Xiamen Aomu Trade Co., Ltd from Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) for CNY 0.

New 90-day low - CN¥20.10

Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363) completed the acquisition of the remaining 70% stake in Xiamen Yinxiang Meat Industry Co., Ltd. from Xiamen Yinxiang Group Co., Ltd.

New 90-day high - CN¥26.31

Earnings released

Fujian Aonong Biological Technology Group Incorporation Limited to Report First Half, 2020 Results on Aug 20, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş